GALECTIN THERAPEUTICS INC. Share-based Payment Arrangement, Expense
GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Payment Arrangement, Expense of $963.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $963.00K, a 92.60% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $775.00K, a 65.60% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $192.00K, a 82.62% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $498.00K, a 3.30% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2025 was $1.66M, a 32.33% decline from fiscal 2024.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2024 was $2.45M, a 8.23% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2023 was $2.26M, a 21.14% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2022 was $2.87M, a 38.10% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $963.00K 10-Q · filed 2026-08-14 | $1.74M 10-Q · filed 2026-08-14 | $1.93M derived: sum of 3 quarters · filed 2026-08-14 | $2.43M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $775.00K 10-Q · filed 2026-05-15 | $967.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.47M derived: sum of 3 quarters · filed 2026-05-15 | $1.97M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $690.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.19M derived: sum of 3 quarters · filed 2026-08-14 | $1.66M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $498.00K 10-Q · filed 2025-11-14 | $998.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.46M 10-Q · filed 2025-11-14 | $2.57M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-14 | $966.00K 10-Q · filed 2026-08-14 | $2.07M derived: sum of 3 quarters · filed 2026-08-14 | $2.59M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $468.00K 10-Q · filed 2026-05-15 | $1.57M derived: sum of 2 quarters · filed 2026-05-15 | $2.09M derived: sum of 3 quarters · filed 2026-05-15 | $2.83M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.62M derived: sum of 2 quarters · filed 2026-03-31 | $2.36M derived: sum of 3 quarters · filed 2026-03-31 | $2.45M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $515.00K 10-Q · filed 2025-11-14 | $1.25M derived: sum of 2 quarters · filed 2025-11-14 | $1.34M 10-Q · filed 2025-11-14 | $2.26M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $738.00K 10-Q · filed 2025-08-14 | $737.00K 10-Q · filed 2024-08-13 | $1.34M 10-Q · filed 2025-08-14 | $1.75M derived: sum of 3 quarters · filed 2025-08-14 | $2.33M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $604.00K 10-Q · filed 2025-05-15 | $1.01M derived: sum of 2 quarters · filed 2025-05-15 | $1.59M derived: sum of 3 quarters · filed 2025-05-15 | $2.11M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $991.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.51M derived: sum of 3 quarters · filed 2025-03-31 | $2.26M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $586.00K 10-Q · filed 2024-11-14 | $1.10M derived: sum of 2 quarters · filed 2024-11-14 | $1.86M 10-Q · filed 2024-11-14 | $1.76M 10-Q · filed 2023-11-13 | $2.44M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $516.00K 10-Q · filed 2024-08-13 | $1.18M 10-Q · filed 2024-08-13 | $1.86M derived: sum of 3 quarters · filed 2024-08-13 | $2.54M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $662.00K 10-Q · filed 2024-05-15 | $1.34M derived: sum of 2 quarters · filed 2024-05-15 | $2.02M derived: sum of 3 quarters · filed 2024-05-15 | $2.67M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.36M derived: sum of 2 quarters · filed 2024-03-29 | $2.01M derived: sum of 3 quarters · filed 2024-03-29 | $2.87M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $681.00K 10-Q · filed 2023-11-13 | $1.33M derived: sum of 2 quarters · filed 2023-11-13 | $2.19M 10-Q · filed 2023-11-13 | $2.84M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $647.00K 10-Q · filed 2023-08-14 | $1.50M 10-Q · filed 2023-08-14 | $2.16M derived: sum of 3 quarters · filed 2023-08-14 | $2.75M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $858.00K 10-Q · filed 2023-05-15 | $1.51M derived: sum of 2 quarters · filed 2023-05-15 | $2.10M derived: sum of 3 quarters · filed 2023-05-15 | $2.68M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.24M derived: sum of 2 quarters · filed 2023-03-30 | $1.82M derived: sum of 3 quarters · filed 2023-03-30 | $2.08M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $587.00K 10-Q · filed 2022-11-14 | $1.17M derived: sum of 2 quarters · filed 2022-11-14 | $1.42M 10-Q · filed 2022-11-14 | $1.99M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $581.00K 10-Q · filed 2022-08-15 | $835.00K 10-Q · filed 2022-08-15 | $1.40M derived: sum of 3 quarters · filed 2022-08-15 | $1.81M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $254.00K 10-Q · filed 2022-05-16 | $821.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.23M derived: sum of 3 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $975.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.80M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $408.00K 10-Q · filed 2021-11-15 | $1.23M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |